Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

Published:2020-10-31 Issue:2 Volume:100 Page:517-527
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Yuan Xiao-Lin,Tan Ya-Min,Shi Ji-Min,Zhao Yan-Min,Yu Jian,Lai Xiao-Yu,Yang Lu-Xin,Huang He,Luo Yi

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-04326-6.pdf

Reference48 articles.

1. van den Brink MRM, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, Bishop MR (2010) Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 16(1):S138–S145. https://doi.org/10.1016/j.bbmt.2009.10.023

2. Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y, Kanamori H (2014) Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 20(11):1785–1790. https://doi.org/10.1016/j.bbmt.2014.07.010

3. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V, Party EALW (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938–4945. https://doi.org/10.1200/JCO.2007.11.6053

4. Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4(9):1245–1253. https://doi.org/10.1001/jamaoncol.2018.2091

5. Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY, Qin YZ, Wang Y, Huang XJ (2013) Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 92(8):1111–1119. https://doi.org/10.1007/s00277-013-1733-1

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study;Bone Marrow Transplantation;2023-10-31

2. Prophylactic versus Preemptive Modified Donor Lymphocyte Infusion for High-risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study;2023-06-26

3. A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation;Bone Marrow Transplantation;2023-04-18

4. Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation;Transplantation and Cellular Therapy;2022-06

5. Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering;Frontiers in Oncology;2022-01-27